ESMO 2019: Dr. Choueiri Discusses Novel Treatment Strategies in GU Cancers

• Date :
• 3    
  0

OncLive News Network On Location: ESMO 2019 Day 1

• Date :
• 2    
  0

ESMO 2019 Expert Video Report in Upper Gastrointestinal Cancers

• Date :
• 2    
  0

ESMO 2019 Expert Video Report on Carcinoma of Unknown Primary

• Date :
• 2    
  0

ESMO 2019 Highlights in advanced cholangiocarcinoma: The ClarIDHy study

• Date :
• 2    
  0

#ESMO19 Caroline Dive: RAS signalling and cancer

• Date :
• 2    
  0

OncLive News Network On Location: ESMO 2019 Day 3

• Date :
• 1    
  0

ESMO 2019: Dr. O'Shaughnessy Highlights Progress in Breast Cancer

• Date :
• 1    
  0

ESMO 2019 Expert video Report on Neuroendocrine Tumours

• Date :
• 1    
  0

INVICTUS trial: positive results for patients with GIST

• Date :
• 1    
  0

ESMO 2019 Highlights in HER2 negative advanced gBRCA associated breast cancer: The BROCADE3 study

• Date :
• 1    
  0

ESMO 2019 Highlights in metastatic colorectal cancer: The HERACLES-B study

• Date :
• 1    
  0

ESMO 2019 Highlights on circulating tumor DNA: The IDEA-FRANCE study

• Date :
• 1    
  0

#ESMO19 highlights: Jean-Yves Blay and Anton Berns

• Date :
• 1    
  0

ESMO Congress 2019 Daily Reporter - Editor's Picks: Gastrointestinal cancer

• Date :
• 1    
  0

NEPA to prevent chemotherapy-induced nausea and vomiting

• Date :
• 1    
  0

Cancer detecting and locating: cell-free DNA

• Date :
• 1    
  0

PAOLA-1 Phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer

• Date :
• 1    
  0

CheckMate 227 dual IO therapy: nivo plus ipilimumab upfront for NSCLC

• Date :
• 1    
  0

Metastatic melanoma: MART-1 T-cell receptor modified T-cells

• Date :
• 1    
  0

IMvigor130: atezolizumab +/- platinum-based chemo upfront for advanced urothelial carcinoma

• Date :
• 1    
  0

CUPISCO & GEFCAPI04: molecularly-guided therapy in cancer of unknown primary

• Date :
• 1    
  0

The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIA

• Date :
• 1    
  0

ESMO 2019: Dr. Spigel Highlights Progress in Lung Cancer

• Date :
• 0    
  0

ESMO 2019: Dr. Rugo Highlights Progress in Breast Cancer

• Date :
• 0    
  0

Experts Highlight Anticipated Research to Be Revealed at ESMO 2019

• Date :
• 0    
  0

ESMO 2019: Dr. McGregor Highlights Impactful 2019 Prostate Cancer Studies

• Date :
• 0    
  0

Other Noteworthy Data From the 2019 ESMO Meeting

• Date :
• 0    
  0

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

• Date :
• 0    
  0

ESMO 2019: Dr. Hamid Discusses Exciting Immunotherapy Data in Melanoma

• Date :
• 0    
  0

ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer

• Date :
• 0    
  0

ESMO 2019 Expert Video Report on Small Cell Lung Cancer

• Date :
• 0    
  0

ESMO 2019 Expert Video Report on Malignant Pleural Mesothelioma

• Date :
• 0    
  0

ESMO 2019 Expert Video Report on Breast Cancer

• Date :
• 0    
  0

ESMO 2019 Expert Video Report on Prostate Cancer

• Date :
• 0    
  0

ESMO 2019 Expert Video Report on ovarian cancer

• Date :
• 0    
  0

ESMO 2019 Expert Video Report on immune checkpoint inhibitors in MSI-High tumours

• Date :
• 0    
  0

ESMO 2019 Highlights in locally advanced head and neck cancer: A GORTEC Study

• Date :
• 0    
  0

ESMO 2019 Highlights in metastatic castration resistant prostate cancer: The PROFOUND study

• Date :
• 0    
  0

ESMO 2019 Highlights in HR+ HER2? advanced breast cancer: The MONALEESA-3 study

• Date :
• 0    
  0

ESMO 2019 Highlights in urothelial carcinoma: The IMvigor130 study

• Date :
• 0    
  0

Fake news in cancer: how oncologists can address the issue

• Date :
• 0    
  0

ESMO 2019 Highlights in advanced non small cell lung cancer: The CheckMate 227 study

• Date :
• 0    
  0

ESMO 2019 Highlights on advanced ovarian cancer: The PAOLA-1 study

• Date :
• 0    
  0

ESMO 2019 Highlights in Advanced Melanoma: The CHECKMATE 067 study

• Date :
• 0    
  0

ESMO 2019 Highlights in stage IV melanoma: The IMMUNED Study

• Date :
• 0    
  0

IPI plus NIVO shows efficacy in resected stage IV melanoma

• Date :
• 0    
  0

Common but still rare: What happens when common cancers split into subgroups?

• Date :
• 0    
  0

Final overall survival (OS) data from FLAURA trial

• Date :
• 0    
  0

Prostate cancer, what is the optimal timing for radiotherapy?

• Date :
• 0    
  0

ESMO 2019: Translating science into better cancer care

• Date :
• 0    
  0

#ESMO19: Translating science into better cancer patient care

• Date :
• 0    
  0

What to expect at #ESMO19: Josep Tabernero

• Date :
• 0    
  0

#ESMO19 Caroline Dive: Basic Science track

• Date :
• 0    
  0

#ESMO19 Florian Scotté: Supportive & Palliative Care track

• Date :
• 0    
  0

#ESMO19 Sabine Linn: Translational Research track

• Date :
• 0    
  0

Follow the ESMO Congress 2019 on the new digital Daily Reporter

• Date :
• 0    
  0

ESMO Congress 2019 Daily Reporter – Supervisor's Picks: Top stories

• Date :
• 0    
  0

ESMO Congress 2019 Daily Reporter – Editor-in-Chief's Picks: Top stories

• Date :
• 0    
  0

ESMO Congress 2019 Daily Reporter - Editor's Picks: Prostate cancer

• Date :
• 0    
  0

ESMO 2019: Stay up-to-date with the new digital Daily Reporter

• Date :
• 0    
  0

ESMO 2019 Daily Reporter - Editor's Picks: Ovarian cancer

• Date :
• 0    
  0

ESMO 2019 Daily Reporter - Editor's Picks: Lung cancer

• Date :
• 0    
  0

#ESMO19 Lisa Licitra: HPV vaccination for everybody?

• Date :
• 0    
  0

#ESMO19 Ian Chau: Caloric restriction mimetics, autophagy and #cancer

• Date :
• 0    
  0

Erdafitinib for bladder cancer: more to come following FDA approval

• Date :
• 0    
  0

Atezolizumab and bevacizumab for upfront unresectable HCC

• Date :
• 0    
  0

Prof. Siefker-Radtke on the EV-103 trial in bladder cancer

• Date :
• 0    
  0

Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma

• Date :
• 0    
  0

Dr Camidge on novel NSCLC agents: we want to see the duration of benefit

• Date :
• 0    
  0

Biomarker-directed BISCAY data: durvalumab plus targeted therapies in mUC

• Date :
• 0    
  0

The Pitfalls of cell-free DNA sequencing

• Date :
• 0    
  0

Supportive care in cancer: more is needed

• Date :
• 0    
  0

Cell-free DNA sequencing in the clinical setting

• Date :
• 0    
  0

FLAURA final analysis: osimertinib for first-line EGFRm NSCLC

• Date :
• 0    
  0

Adoptive cell therapy in metastatic melanoma

• Date :
• 0    
  0

No clear evidence for benefit with addition of Rova-T to chemo for extensive SCLC

• Date :
• 0    
  0

Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma

• Date :
• 0    
  0

Nab-paclitaxel and gemcitabine in soft tissue sarcoma: trial update

• Date :
• 0    
  0

Long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: ABC trial data

• Date :
• 0    
  0

FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

• Date :
• 0    
  0

OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma

• Date :
• 0    
  0

Niraparib in newly diagnosed advanced ovarian cancer: PRIMA results

• Date :
• 0    
  0

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer

• Date :
• 0    
  0

Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC

• Date :
• 0    
  0

MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancer

• Date :
• 0    
  0

BYLieve additional cohort: update on the trial of alpelisib in advanced breast cancer from ESMO

• Date :
• 0    
  0

AMG 510 for targeting KRAS G12C mutant solid tumours

• Date :
• 0    
  0

Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts

• Date :
• 0    
  0

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

• Date :
• 0    
  0

Targeted therapy in TNBC

• Date :
• 0    
  0

Oncologists' role in cancer prevention

• Date :
• 0    
  0

Sym015: MET antibody mixture for advanced solid tumors

• Date :
• 0    
  0

SPICE trial: enadenotucirev with nivolumab in tumors of epithelial origin

• Date :
• 0    
  0

IMpower110: atezolizumab vs chemo in PD-L1selected NSCLC

• Date :
• 0    
  0

Efficacy of lorlatinib in NSCLC post-second generation ALK TKI

• Date :
• 0    
  0

Optimizing CRC and uHCC outcomes with TKIs

• Date :
• 0    
  0

I-O in Gastric/GEJ cancer

• Date :
• 0    
  0

Blood first assay screening in treatment-naïve NSCLC: initial results from the ALK+ cohort

• Date :
• 0    
  0

MSI-H status in advanced G/GEJ

• Date :
• 0    
  0

Oncology HCPs online: balancing cancer education internationally

• Date :
• 0    
  0

CheckMate 227: chemo-free NSCLC treatment

• Date :
• 0    
  0

Twitter oncology networks: interview with @weoncologists on the @OncoAlert movement

• Date :
• 0    
  0

PROfound performance: olaparib vs. enzalutamide or abiraterone for HRR altered mCRPC

• Date :
• 0    
  0

One to watch: KEYNOTE-866, perioperative pembro with neoadjuvant chemo in MIBC

• Date :
• 0    
  0

Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma

• Date :
• 0    
  0

Updated FIERCE-22 data: vofatamab with pembrolizumab for mUC

• Date :
• 0    
  0

POLARIS: encorafenib/binimetinib for advanced BRAFV600+ melanoma

• Date :
• 0    
  0

PARP inhibitors for ovarian cancer

• Date :
• 0    
  0

Rucaparib maintenance for recurrent ovarian carcinoma

• Date :
• 0    
  0

SUNEVO: sunitinib/evofosfamide for metastatic pancreatic NETs

• Date :
• 0    
  0

ETOP NICOLAS: nivolumab, chemotherapy and radiotherapy for NSCLC

• Date :
• 0    
  0

Social networks in medicine: US to Europe and beyond

• Date :
• 0    
  0

Lurbinectedin monotherapy is active in progressive malignant pleural mesothelioma: SAK 17/16 results

• Date :
• 0    
  0

FORWARD I: mirvetuximab soravtansine vs chemo in platinum-resistant ovarian cancer

• Date :
• 0    
  0

Who are the long-term responders to immuno and targeted therapy in melanoma?

• Date :
• 0    
  0

ESMO priorities

• Date :
• 0    
  0

PD1 & PDL1 inhibitors for mUC, where are we?

• Date :
• 0    
  0

#women4onco with Solange Peters

• Date :
• 0    
  0

GAP study: nab-paclitaxel & gemcitabine in locally advanced, unresectable pancreatic cancer

• Date :
• 0    
  0

AVANT: bevacizumab + oxaliplatin-based chemo for colon cancer

• Date :
• 0    
  0

Aligning the educational resources put out by ESMO

• Date :
• 0    
  0

IMvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer

• Date :
• 0    
  0

IMpower133: atezolizumab, carboplatin plus etoposide for SCLC

• Date :
• 0    
  0

Pancreatic cancer: moving forward

• Date :
• 0    
  0

PROMISE-meso: pembrolizumab vs. standard chemotherapy for mesothelioma

• Date :
• 0    
  0

CheckMate 227 update

• Date :
• 0    
  0

Pancreatic Cancer: peri-operative precision

• Date :
• 0    
  0

Urothelial carcinoma: maintenance therapies

• Date :
• 0    
  0

ALK-positive NSCLC: CNS progression

• Date :
• 0    
  0

The immunotherapy NSCLC revolution

• Date :
• 0    
  0

Cell-Free DNA for GI therapy personalization

• Date :
• 0    
  0

irAEs with single-agent PD-1 vs PD-L1 inhibitors

• Date :
• 0    
  0

SB8: a bevacizumab biosimilar for NSCLC

• Date :
• 0    
  0

John Strickler: ESMO 2019 Highlights

• Date :
• 0    
  0

PARP inhibitors for ovarian cancer - room for improvement with HRD testing

• Date :
• 0    
  0

IDEA-FRANCE: ctDNA as a predictive value for adjuvant treatment duration

• Date :
• 0    
  0

Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin

• Date :
• 0    
  0

Melanoma news from ESMO 19

• Date :
• 0    
  0

Kidney cancer: post-surgery sorafenib

• Date :
• 0    
  0

Improving patient selection for surgical candidates with head and neck cancer

• Date :
• 0    
  0

Update on oncolytic viruses for cancer treatment

• Date :
• 0    
  0

The value of PD-L1 as a biomarker beyond lung cancers

• Date :
• 0    
  0

PATRIOT: ATR inhibitor monotherapy in advanced solid tumors

• Date :
• 0    
  0

MOUNTAINEER results: trastuzumab and tucatinib for HER2+ mCRC

• Date :
• 0    
  0

CheckMate 459: updates on nivolumab monotherapy for HCC

• Date :
• 0    
  0

Urothelial carcinoma: apatorsen plus docetaxel does not provide significant value

• Date :
• 0    
  0

ILLUMINATE 101: Updates and implications on colorectal cancer

• Date :
• 0    
  0

Molecular target therapy in pancreatic and liver cancer

• Date :
• 0    
  0

Preliminary findings in mCRPC for fractionated dose 177Lu-PSMA-617

• Date :
• 0    
  0

Early diagnosis in advanced pancreatic cancer: how will we achieve this?

• Date :
• 0    
  0

Phase III trial: chemotherapy plus local-regional radiotherapy in pmNPCC

• Date :
• 0    
  0

Melanoma musings: Dr Ascierto's trial updates from ESMO

• Date :
• 0    
  0

An update on NSGO

• Date :
• 0    
  0

NPC communication between the West and China

• Date :
• 0    
  0

Gynecological cancer: not yet ready for a chemo-free era

• Date :
• 0    
  0

First-line treatment guidelines: combination strategy

• Date :
• 0    
  0

Combination therapy in gynecoligcal cancer

• Date :
• 0    
  0

NIVOREN GETUG-AFU 26: Updates and implications

• Date :
• 0    
  0

Standard of care updates in ovarian cancer: PARP inhibitors

• Date :
• 0    
  0

Congrès ESMO 2026

• Date :
• 798    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date :
• 1312    
  0

SABCS 2025 Symposium

• Date :
• 7706    
  0

Congrès ESMO Asie 2025

• Date :
• 948    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date :
• 1409    
  0